OXcan develops blood tests for early cancer detection utilizing advanced proteomics and artificial intelligence. The company focuses on improving diagnostic accuracy, particularly in complex areas like lung disease staging. This technology aims to enable earlier intervention and more effective curative treatment pathways for cancer patients.
Funding
$17.4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
CBWVFounders
Product
Problem
Traditional cancer detection methods often rely on invasive tissue biopsies and complex imaging techniques, which can be costly, time-consuming, and pose risks to patients. These methods may also fail to detect cancers at an early stage when treatment is most effective.
Solution
Oxford Cancer Analytics (OXcan) offers a machine-learning platform designed to analyze cancer biomarkers in blood samples, enabling early cancer detection through minimally invasive liquid biopsy tests. The DEcancer platform aims to provide a safer and more cost-effective alternative to traditional methods, identifying curable cancers at an earlier stage. By analyzing specific molecules in the blood, the platform can detect signs of cancer before symptoms appear or through less invasive procedures than traditional biopsies. The goal is to enable curative cancer treatment through early detection.
Target Audience
OXcan's primary customers are healthcare providers and organizations focused on early cancer detection in high-risk populations.
Features
- Machine learning-driven analysis of cancer biomarkers in blood samples
- Minimally invasive liquid biopsy tests
- DEcancer platform for early cancer detection
- Versatile application for various cancer types